abstract |
The present invention relates to the novel family of receptor tyrosine kinases, herein referred to as MCK-10, to nucleotide sequences and expression vectors encoding MCK-10, and to methods of inhibiting MCK-10 activity. The invention relates particularly to one member of the MCK-10 receptor tyrosine kinase family, the CCK-2 receptor tyrosine kinase. Genetically engineered host cells that express CCK-2 may be used to evaluate and screen drugs involved in CCK-2 activation and regulation. The invention relates to the use of such drugs, in the treatment of proliferative disorders, including cancer or neurological disorders, by modulating the activity of CCK-2. |